Glioblastoma / Brain Tumor Research Reagents

Glioblastoma (GBM, WHO grade 4) is the most common and lethal primary brain malignancy in adults. The 2021 WHO CNS tumor classification integrates molecular markers (IDH mutation, 1p/19q codeletion, CDKN2A/B deletion) with histology for definitive grading. Standard treatment remains temozolomide with concurrent radiotherapy (Stupp protocol), with MGMT promoter methylation predicting temozolomide benefit.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Glioblastoma Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets in glioblastoma. IDH mutation-based molecular classification, EGFR/EGFRvIII signaling, GFAP lineage identification, and MGMT-mediated chemoresistance. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key glioblastoma and brain tumor research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

IDH1 R132H — IDH1 R132H mutation is the most common IDH mutation in diffuse gliomas, producing D-2-hydroxyglutarate (2-HG) that drives epigenetic reprogramming. The R132H-specific antibody enables IHC-based molecular classification — distinguishing IDH-mutant from IDH-wildtype glioblastoma, a distinction with major prognostic and therapeutic implications.
→ Browse IDH1 antibodies & proteins

EGFR / EGFRvIII — EGFR amplification occurs in approximately 57% of IDH-wildtype GBM, and the EGFRvIII truncation variant is present in 25–30% of these cases. Anti-EGFR and EGFRvIII-specific antibodies support IHC amplification assessment, variant-specific detection, and CAR-T/vaccine immunotherapy target validation studies.
→ Browse EGFR antibodies & proteins

GFAP — GFAP is the canonical astrocytic lineage marker essential for glioma histological classification. Anti-GFAP antibodies are validated for IHC and IF-based lineage confirmation, tumor margin delineation, and serum GFAP measurement as a minimally invasive biomarker for glioma detection and monitoring.
→ Browse GFAP antibodies & ELISA kits

MGMT — MGMT promoter methylation predicts benefit from temozolomide alkylating chemotherapy. Anti-MGMT antibodies support protein expression studies that complement methylation-specific PCR testing and enable research into MGMT-mediated chemoresistance mechanisms.
→ Browse MGMT antibodies & proteins

References

1. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. DOI

2. Louis DN, et al. The 2021 WHO Classification of Tumors of the Central Nervous System. Neuro Oncol. 2021;23(8):1231-1251. DOI

3. Brennan CW, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477. DOI

4. Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003. DOI

5. Verhaak RGW, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma. Cancer Cell. 2010;17(1):98-110. DOI